Laboratory Medicine Program

Acute Leukemia: Malignant Hematology NGS panel (Acute Myeloid Leukemia)
(Funded by MOH for new diagnosis)

Clinical Decription:
Multiple gene panel for diagnosis, risk assessment and therapy assessment in Acute Myeloid Leukemia (AML). Next generation sequencing is used to detect sequence variants AML diagnostic biomarkers as well as genes associated with favorable or poor prognosis in AML. Results can be integrated with results of other molecular and cytogenetic tests, including G-banded karyotype and allele specific PCR analysis for specific FLT3 and NPM1 variants, to provide comprehensive risk assessment.

Method: Next-Generation Sequencing (NGS)

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Peripheral Blood/Bone Marrow/FFPE
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Gene (ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, CTNNA1, CUX1, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA2, GNAS, IDH1, IDH2, IKZF1, IRF1, JAK1, JAK2, KIT, KMT2A, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PAX5, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2) See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227